ReviewOpen forum infectious diseases2019
Review in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Article
- Mindful diagnostics in culture-negative endocarditis: early noninvasive diagnosis ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Article
- Article
- A Family at War-AgainstOpen forum infectious diseases · 2025Article
- Advances and Prospects in the Diagnosis and Treatment of Blood Culture-Negative Infective Endocarditis.Reviews in cardiovascular medicine · 2025Review
- A new case ofOxford medical case reports · 2025Article
- Whipple's Disease as a Differential Diagnosis of Blood Culture-Negative Endocarditis: A Case Report.Arquivos brasileiros de cardiologia · 2025Article
- From Culture-Negative to DNA-Positive: The Molecular Revolution in Infective Endocarditis Diagnosis.Pathogens (Basel, Switzerland) · 2025Review
- Article
- Failure or future? Exploring alternative antibacterials: a comparative analysis of antibiotics and naturally derived biopolymers.Frontiers in microbiology · 2025Review
- Severe mitral valve papillary muscle rupture of isolated Whipple's endocarditis: a case report and review of the literature.Frontiers in cardiovascular medicine · 2025Article
- [Endocarditis and ischemic stroke of rare cause].Innere Medizin (Heidelberg, Germany) · 2024Article
- Article
- Tropheryma whipplei Endocarditis Presenting as Valvulopathy and Multiple Septic Emboli.Journal of general internal medicine · 2024Article
- Uncommon pathogens causing infective endocarditis.Indian journal of thoracic and cardiovascular surgery · 2024Review
- Lyme disease and Whipple's disease: a comprehensive review for the rheumatologist.Advances in rheumatology (London, England) · 2024Review
- Novel Diagnostic Methods for Infective Endocarditis.International journal of molecular sciences · 2024Review
- A Dual-Pathogen Mitral Valve Endocarditis Caused byPathogens (Basel, Switzerland) · 2023Article
- Updates in Culture-Negative Endocarditis.Pathogens (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whipple's disease is a rare infective condition, classically presenting with gastrointestinal manifestations. It is increasingly recognized as an important cause of culture-negative endocarditis. We present a case of Whipple's endocarditis presenting with heart failure. A literature review identified 44 publications documenting 169 patients with Whipple's endocarditis. The average age was 57.1 years. There is a clear sex predominance, with 85% of cases being male. Presenting symptoms were primarily articular involvement (52%) and heart failure (41%). In the majority of cases, the diagnosis was made on examination of valvular tissue. Preexisting valvular abnormalities were reported in 21%. The aortic valve was most commonly involved, and multiple valves were involved in 64% and 23% of cases, respectively. Antibiotic therapy was widely varied and included a ceftriaxone, trimethoprim, and sulfamethoxazole combination. The average follow-up was 20 months, and mortality was approximately 24%. Physician awareness is paramount in the diagnosis and management of this rare condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.